The approval is based on evidence that the vaccine can prevent anogenital infections, with an ongoing trial looking at throat infection prevention in men likely to be critical for continued approval.
Clinicians must consider patient sexual history in the decision-making process for adult HPV vaccination.
Lack of parental intent to initiate and complete the human papillomavirus (HPV) vaccine series for adolescents is a major public health concern.
The FDA has granted Orphan Drug designation to INO-3107, a DNA plasmid immunotherapy, for the treatment of recurrent respiratory papillomatosis, a rare disease caused by human papillomavirus types 6 and 11 infections.
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.
In addition to high antibody levels, factors including exposure to the human papillomavirus (HPV) and antibody avidity may be important and necessary to protect against infection.
For patients with oropharynx cancer, the rates of head and neck cancer mortality and competing mortality vary depending on HPV status.
From 2013 to 2018, there was an increase in the percentage of adults aged 18 to 26 years who received one or more doses or the recommended number of doses of HPV vaccine.
Only one in four patients with sinonasal squamous cell carcinoma is tested for human papillomavirus.
